services as a foreign medication or for compassionate use. The usual dose is 100 mg/day, and adverse effects include yellow discoloration of mucocutaneous zones, lichenoid eruption, aplastic anemia, headache, gastrointestinal symptoms, psychosis, convulsions and worsening of psoriasis. As yellowing of the skin and the whites of the eyes is very common, patients should be advised of this side effect before starting treatment. The majority of patients tolerate this discoloration, which usually occurs during the first weeks of treatment and resolves completely when treatment is discontinued. While the cause of the discoloration remains unknown, it is not due to hyperbilirubinemia and is related to the cumulative dose. In a series of 8 patients with cutaneous lupus erythematosus who were treated with quinacrine, the majority responded favorably, although 50% developed yellow skin discoloration. In summary, despite its multiple adverse effects, quinacrine is a useful drug for the treatment of patients with cutaneous lupus erythematosus with retinopathy. In our patient, quinacrine helped to resolve cutaneous lupus erythematosus and made possible a reduction in the dose of prednisone, although skin toxicity eventually led to withdrawal of the treatment.

References

D. Vidal, a,∗ J. Altés, a J.A. Smandia b

a Servicios de Medicina Interna, Hospital de Sant Joan Despí Moisés Broggi, Barcelona. Consorci Sanitari Integral, Barcelona, Spain
b Servicios de Dermatología, Hospital de Sant Joan Despí Moisés Broggi, Barcelona. Consorci Sanitari Integral, Barcelona, Spain

∗Corresponding author.
E-mail address: vidal@sanitatintegral.org (D. Vidal).

Allergic Contact Dermatitis Due To Chlorocresol In Topical Corticosteroids∗

Eccema alérgico de contacto por clorocresol contenido en corticoides tópicos

To the Editor:
Allergic contact dermatitis to medicinal products containing topical corticosteroids may be caused by the corticosteroid itself or by the excipients. We report a 40-year-old man with allergic contact dermatitis to chlorocresol, a preservative used in several topical corticosteroid preparations. The patient presented to our clinic 8 years earlier having been diagnosed in another centre with atopic dermatitis since childhood. In recent years the lesions had predominantly affected the hands and feet, so patch tests were performed with the standard series of the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC), showing positivity for chromium. This finding was considered relevant because the patient wore leather shoes and worked as a waiter carrying metal trays. The diagnosis of allergic contact dermatitis to chromium was added. The patient changed jobs and avoided contact with metal but did not use chrome-free footwear regularly. In the following years the intensity fluctuated and was managed with topical corticosteroids, although systemic treatment was required for severe and prolonged flare-ups. These treatments consisted of tapering doses of oral prednisone, 2 cycles of ciclosporin A (5 mg/kg), for 6 and 9 months, and 1 cycle of oral methotrexate (20 mg weekly) for 8 months. With these treatments the patient achieved episodes of almost complete remission lasting several months, during

∗ Please cite this article as: Gómez de la Fuente E, et al. Eccema alérgico de contacto por clorocresol contenido en corticoides tópicos. Actas Dermosifiliogr. 2013;104:90-2.
which he controlled the residual dermatitis with topical corticosteroids. However, in the last year the patient had begun to have flare-ups of disseminated, intensely pruritic, exudative eczematous lesions affecting the trunk, face, arms, legs, and palms (Fig. 1). As treatment with oral prednisone (1 mg/kg) produced only a transient response, oral cyclosporin was again prescribed at a dosage of 5 mg/kg but almost no response was achieved. Given the change in morphology of the lesions and the absence of a satisfactory response, the patch tests were repeated with the GEIDAC standard series, a cosmetics series (Chemotechnique), and various products used by the patient, including hygiene and hydration products and several topical corticosteroids (Clovate cream, Fucibet cream, Adventan cream and Decloban ointment). The readings at 48 and 96 hours were positive (++) for 1% chlorocresol in petrolatum, Clovate cream, and Fucibet cream. It was found that chlorocresol was included in the formulation of these corticosteroids and a subsequent patch test with a corticosteroid series (Martí T or) showed no additional sensitization. After avoiding this allergen, the patient improved and is currently controlled with clobetasol propionate ointment (Decloban) without adverse effects.

Chlorocresol (p-chloro-m-cresol) is a biocide used as a disinfectant and preservative in a wide range of products. It is currently found in a 1% concentration in petrolatum, Clovate cream, and Fucibet cream. It was found that chlorocresol was included in the formulation of these corticosteroids and a subsequent patch test with a corticosteroid series (Martí T or) showed no additional sensitization. After avoiding this allergen, the patient improved and is currently controlled with clobetasol propionate ointment (Decloban) without adverse effects.

Chlorocresol is widely used in various medicinal products such as insulins and heparins. It has also been reported to cause skin reactions (sometimes serious) due to chlorocresol present in other medicinal products such as insulins and heparins. 

In Spain chlorocresol is used as a preservative in many topical corticosteroids (Table 1), but few cases have been reported in the literature. Skin reactions (sometimes severe) caused by chlorocresol present in other medicinal products such as insulins and heparins have also been reported. It should not be forgotten that, though rarely, it can also cause contact urticaria. Cross-reactivity has been reported with chloroxylenol (p-chloro-m-xylanol), another preservative with a very similar chemical structure (Fig. 2). In our case there was no sensitization to chloroxylenol, as found in other cases in which the primary sensitization was through topical corticosteroids. On the basis of a case and a review of the literature, Lewis and Emmett speculated that this cross-reactivity occurred only when the initial sensitization was to chloroxylenol rather than chlorocresol. Yamano et al. demonstrated bidirectional cross-reactivity in animals but a much lower concentration was necessary when the initial sensitization was through chloroxylenol. The case presented underlines the importance of conducting patch tests in eczematous conditions with unjustified exacerbations and ones that do not respond well to treatment. The tests should include products and topical drugs used by the patient and should evaluate the active ingredients, the preservatives, and the excipients.

### References

4. Lewis PG, Emmet EA. Irritant dermatitis from tributyl tin oxide and contact allergy from chlorocresol. Contact Dermatitis. 1987;17:129–32.
Dermoscopy of Early Dissecting Cellulitis of the Scalp Simulates Alopecia Areata

La dermatoscopia de la celulitis disecante precoz del cuero cabelludo es similar a la alopecia areata

To the Editor:

Dissecting cellulitis of the scalp (DCS) is a follicular occlusion disorder that may progressively lead to scarring alopecia. It presents as multifocal painful nodules and boggy plaques with alopecia which is reversible in early disease, but can become scarring in longstanding lesions.1 Dermoscopy is an useful non-invasive method for diagnosis and management of hair and scalp disorders, including cicatricial alopecia, such as lichen planopilaris, lupus erythematosus, and folliculitis decalvans.2-5

Figure 1  Alopecic patches with discrete nodules of DCS, resembling AA.

Figure 2  (a) Dermoscopy showing yellow dots, empty follicular openings, black dots and cadaverized hairs, very similar to AA. Exclamation mark hairs were absent. (Dermoscopy, at 40× magnification.) (b) Dermoscopy of follow-up, showing short regrowing hairs and dystrophic hairs. (Dermoscopy, at 70× magnification.)


E. Gómez de la Fuente,* M. Andreu-Barasoain, A. Nuño-González, J.L. López-Esteban

Servicio Dermatología, Hospital Universitario Fundación Alcorcón, Madrid, Spain

*Corresponding author. E-mail address: egomezf@hualcorcon.es (E. Gómez de la Fuente).